Substantial advances in prostate cancer management have been made with noninvasive imaging techniques including radionuclide imaging and magnetic resonance spectroscopy imaging (MRSI) in addition to conventional structural imaging techniques, computed tomography (CT), magnetic resonance imaging (MRI), and transrectal ultrasonography (TRUS). However, no single imaging technique has demonstrated the breadth of functionality needed to assess prostate cancer. In addition, a coherent multimodality approach using these already available imaging techniques has not been established for the clinical management of this disease. We therefore propose to develop an approach to present a comprehensive set of functional, metabolic, biomolecular, and structural imaging modalities for the same patient to improve management of patients with prostate cancer. The goal of this project is to develop an approach that combines information from multiple imaging modalities and to develop a method to improve the current prostate cancer management in both pretherapy and posttherapy cases. In this study, we will focus on the dual-modality SPECT/CT imaging using an indium-111 radiolabeled monoclonal antibody and MRI/MRSI techniques during initial periods of the project. Goal 1: A method will be developed to quantify 111ln-labeled capromab pendetide (ProstaScint(R), Cytogen Corporation, Princeton, NJ) activity in phantoms and patients with a commercial SPECT/CT system (Discovery VH Hawkeye, GE Healthcare, Waukesha, Wl). The methods of quantifying 111ln-ProstaScint(R) uptake then will be extended to an approach that combines SPECT/CT and MRI/MRSI for assessment of prostate cancer. Goal 2: We will develop methods that correlate SPECT/CT and MRI/MRSI images to evaluate patients at a high risk of having metastasized cancer with a goal of assisting radiation treatment planning. The quantitative measurements and correlations from 111ln-ProstaScint( R)SPECT/CT and MRI/MRSI studies developed from Goal 1 and 2 then can guide radiation therapy planning which will be pursued under Goal 3. Goal 3: A method to implement the correlative image presentation in radiation treatment planning will be developed. We believe that outcomes from the successful completion of the proposed research program will not only enhance the clinical prostate cancer management but also provide valuable aptitude skills and knowledge for the candidate to become an independent biomedical researcher with strong background in quantitative sciences.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Mentored Quantitative Research Career Development Award (K25)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Seo, Youngho; Gustafson, W Clay; Dannoon, Shorouk F et al. (2012) Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol 14:735-42
Mari Aparici, Carina; Seo, Youngho (2012) Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med 42:328-42
Aparici, Carina Mari; Carlson, David; Nguyen, Nhan et al. (2012) Combined SPECT and Multidetector CT for Prostate Cancer Evaluations. Am J Nucl Med Mol Imaging 2:48-54
Sayre, George A; Bacharach, Stephen L; Dae, Michael W et al. (2012) Combining dynamic and ECG-gated ?²Rb-PET for practical implementation in the clinic. Nucl Med Commun 33:4-13
Seo, Youngho; Aparici, Carina Mari; Chen, Chien Peter et al. (2011) Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT. J Nucl Med 52:1068-72
Lee, Chang-Lae; Wahnishe, Hilla; Sayre, George A et al. (2010) Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys 37:4861-7
Seo, Youngho; Aparici, Carina Mari; Cooperberg, Matthew R et al. (2010) In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med 51:31-6
Pan, Mei-Hsiu; Gao, Dong-Wei; Feng, Jinjin et al. (2009) Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy. Mol Imaging Biol 11:159-66
Seo, Youngho; Hashimoto, Tomoki; Nuki, Yoshitsugu et al. (2008) In vivo microCT imaging of rodent cerebral vasculature. Phys Med Biol 53:N99-107
Seo, Youngho; Mari, Carina; Hasegawa, Bruce H (2008) Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 38:177-98

Showing the most recent 10 out of 11 publications